1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Commercial Excellence in Rare Diseases and Orphan Drugs

Commercial Excellence in Rare Diseases and Orphan Drugs

  • June 2015
  • ID: 3090980
  • Format: PDF
  • By Firstword Pharma


Table of Contents

Developing therapies for orphan diseases is attracting much industry interest with the promise of profits. But what are the specific R&D, regulatory, stakeholder and market access issues you need to understand and practically address?

Commercial Excellence in Rare Diseases and Orphan Drugs is a highly-detailed report for industry management who must evaluate, plan, execute, manage and deliver profit from orphan drug programmes. Enriched with case studies, the report reveals the real-world experience and actionable insights of eight senior industry experts who possess a deep knowledge of the challenging and highly-demanding operating environment for orphan drug development and commercialisation.

Gain Answers to Key Questions

How can patients and patient advocacy groups play an enhanced role throughout a product’s development cycle from research funding to market access?
Why is early engagement with payers and KOLs critical in ensuring wide market access and uptake?
To what extent is the accurate assessment of unmet clinical need and establishing potential patient population critical and what are the benchmarks?
With approximately 7,000 identified orphan diseases, how do you select research targets for development?
Clinical trial design and recruitment are challenges for orphan drug developers: what needs to be taken into account and how have companies approached this?
Orphan drug regulation is relatively relaxed, but what more could regulators do and how can you influence them?
Small/Big pharma collaborations: when is the optimum time for engagement and what can each learn from each other?

Top Benefits

Understand how patient support is a must-have for industry and identify the areas where they are most influential
Formulate communication strategies to ensure wide clinical buy-in and support
Address effectively the anxieties of payers who must justify orphan drug spend in their budgets
Examine critical orphan drug candidate selection and overcome challenges of designing and conducting clinical trials
Understand what is considered to be commercial excellence for orphan drugs and what are the hurdles for success
Gain insight into current company structures for orphan drugs and the way in which rare disease teams should be structured in order to maximise commercial success
Understand the regulatory structures that determine orphan drug research/approval and learn where and how regulators can be influenced

Key Takeaways

Orphan drugs offer a positive opportunity for Pharma, but companies must be realistic about their potential and the challenges – old models of assessment used for drugs targeting large patient populations are not fit for purpose
Engagement with key stakeholders at an early stage is critical to ultimate commercial success
Patient Groups, more than any other area, are critical to success and hugely influential in realising a product’s commercial potential
Orphan drugs are often very expensive: make your case to payers, and make it early to ensure buy in
Identifying appropriate research candidates for late phase investment requires a clear understanding of unmet needs and patient population – and how you will access them
Regulators may look positively on orphan drug applications but there are still challenges to overcome
The internal organisation of orphan drug teams varies and the assessment of different models is critical

Report Features – Not Available Elsewhere

Knowledgeable and detailed insights and opinions of eight industry experts working daily in developing and commercialising orphan disease drugs in the US and Europe

Extensive case studies demonstrating different approaches and experiences for ensuring commercial effectiveness

Critical insights for corporate, research, planning, marketing and communications management

Experts Interviewed

Business Unit Head, Rare diseases, Top 10 pharmaceutical company

Senior Director, Top 10 pharmaceutical company

Marketing Director, Mid-size European pharmaceutical company

Sales Director, European pharmaceutical company

Senior Product Manager, Top 10 pharmaceutical company

Director, Rare disease pharmaceutical company

Marketing Director, Top 10 pharmaceutical company

Marketing Director, Top 10 pharmaceutical company

About FirstWord Reports

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Global Drug Delivery Partnering 2014-2019: Deal trends, players and financials

Global Drug Delivery Partnering 2014-2019: Deal trends, players and financials

  • $ 3495
  • November 2019

The Global Drug Delivery Partnering 2014-2019 report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading ...

Global Diagnostics Partnering 2014-2019: Deal trends, players and financials

Global Diagnostics Partnering 2014-2019: Deal trends, players and financials

  • $ 3495
  • November 2019

The Global Diagnostics Partnering 2014-2019 report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading companies.Comprehensive ...

Hypertension Drugs Markets in China

Hypertension Drugs Markets in China

  • $ 4000
  • October 2019

China’s demand for Hypertension Drugs has grown at a fast pace in the past decade.In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth ...

Global Autoinjectors Industry $ 4950 October 2019

Colitis - Pipeline Review, H2 2019 $ 2000 September 2019


Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on